FindTrial
Sign In

Diagnostic efficacy of complete blood count and derived inflammatory biomarkers for diagnosis of rheumatoid arthritis disease activity in rheumatoid arthritis with normal acute phase reactant levels

Diagnostic efficacy of complete blood count and derived inflammatory biomarkers for diagnosis of rheumatoid arthritis disease activity in rheumatoid arthritis with normal acute phase reactant levels

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500098119
Enrollment
Unknown
Registered
2025-03-03
Start date
2025-03-10
Completion date
Unknown
Last updated
2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

Increased levels of reactants in the acute phase of rheumatoid arthritis group:None
Normal reactant levels in the acute phase of rheumatoid arthritis group:None

Sponsors

Chengdu Rheumatism Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Meets the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for RA; 2.Age >=18 years.

Exclusion criteria

Exclusion criteria: 1.Combination of other autoimmune diseases, infections, tumors, etc. 2.Recent use of glucocorticoids or immunosuppressants; 3.Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Complete blood count;—

Secondary

MeasureTime frame
Synovial Thickness Grading;C-reactive protein;Erythrocyte sedimentation rate;Synovial blood flow grading;Number of joints with pressure and pain and number of swollen joints in 28 joints of the patient;Visual analog scoring;—

Countries

China

Contacts

Public ContactJinglin Xia

Chengdu Rheumatism Hospital

cdfsyy01@163.com+86 18384125776

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026